Cyclophosphamide removal from water by nanofiltration and reverse osmosis membrane

Water Research

Volumn 43, Issue 17, 2009, Pages 4115-4122

  Wang, L ^a   Albasi, C ^a   Faucet Marquis, V ^a   Pfohl Leszkowicz, A ^a   Dorandeu, C ^b   Marion, B ^b   Causserand, C ^a  

^a CNRS   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Cyclophosphamide; MBR effluent; Nanofiltration; Removal; Reverse osmosis

Indexed keywords

BIOLOGICAL WATER TREATMENT; BIOREACTORS; IONIC STRENGTH; MEMBRANE FOULING; NANOFILTRATION; OSMOSIS MEMBRANES; REMOVAL; REVERSE OSMOSIS; WATER FILTRATION;

BACKGROUND SOLUTIONS; CYCLOPHOSPHAMIDE; DETECTION METHODS; MBR EFFLUENTS; MEMBRANE BIO REACTOR (MBR); OPERATING CONDITION; REJECTION RATES; TRANSMEMBRANE PRESSURES;

EFFLUENTS;

CYCLOPHOSPHAMIDE; WATER;

BIOREACTOR; DRUG; EFFLUENT; FILTRATION; MEMBRANE; OSMOSIS; POLLUTANT REMOVAL; WATER POLLUTION;

ANALYTIC METHOD; ARTICLE; BIOREACTOR; CHEMICAL INTERACTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EFFLUENT; EXPERIMENTAL DESIGN; EXTRACTION; FOULING CONTROL; FREEZE DRYING; IONIC STRENGTH; MEMBRANE REACTOR; NANOFILTRATION; PRIORITY JOURNAL; REVERSE OSMOSIS; WASTE COMPONENT REMOVAL; WASTE WATER MANAGEMENT;

EID: 69949085869     PISSN: 00431354     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.watres.2009.06.007     Document Type: Article

References (28)

1. Anderson D., Bishop J.B., Garner R.C., Ostrosky-Wegman P., and Selby P.B. Cyclophosphamide - review of its mutagenicity for an assessment of potential germ-cell risks. Mutat. Res. Fundam. Mol. Mech. Mutagen. 330 1-2 (1995) 115-181
2. Bagley C.M., Bostick F.W., and Devita V.T. Clinical pharmacology of cyclophosphamide. Cancer Res. 33 2 (1973) 226-233
3. Bandini S., and Vezzani D. Nanofiltration modeling: the role of dielectric exclusion in membrane characterization. Chem. Eng. Sci. 58 15 (2003) 3303-3326
4. Buerge I.J., Buser H.R., Poiger T., and Muller M.D. Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. Environ. Sci. Technol. 40 23 (2006) 7242-7250
5. Causserand C., Aimar P., Cravedi J.P., and Singlande E. Dichloroaniline retention by nanofiltration membranes. Water Res. 39 8 (2005) 1594-1600
6. Comerton A.M., Andrews R.C., Bagley D.M., and Hao C. The rejection of endocrine disrupting and pharmaceutically active compounds by NF and RO membranes as a function of compound and water matrix properties. J. Membr. Sci. 313 1-2 (2008) 323-335
7. Delgado, L.F., Audran, M., Faucet-Marquis, V., Pfohl-Leszkowicz, A., Schetrite, S., Guibaud, J., Castegnaro, M., Albasi, C., 2008. Performance of a Crossflow Membrane Bioreactor for Hospital Wastewater Treatment: Feasibility? ECWATECH, IWA Congress "Membranes Technologies in Water and Wastewater Treatment" 3-6 June 2008, Moscow, Russia.
8. Grisolia C.K. A comparison between mouse and fish micronucleus test using cyclophosphamide, mitomycin C and various pesticides. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 518 1-2 (2002) 145-150
9. Johnson A.C., Jürgens M.D., Williams R.J., Kümmerer K., Kortenkamp A., John P., and Sumpter J.P. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J. Hydrol. 348 1-2 (2008) 167-175
10. Kasprzyk-Hordern B., Dinsdale R.M., and Guwy A.J. The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK. Water Res. 42 13 (2008) 3498-3518
11. Kim S.D., Cho J., Kim I.S., Vanderford B.J., Shane A., and Snyder S.A. Occurrence and removal of pharmaceuticals and endocrine disruptors in South Korean surface, drinking, and waste waters. Water Res. 41 5 (2007) 1013-1021
12. Kiso Y., Sugiura Y., Kitao T., and Nishimura K. Effects of hydrophobicity and molecular size on rejection of aromatic pesticides with nanofiltration membranes. J. Membr. Sci. 192 1 (2001) 1-10
13. Lindqvist N., Tuhkanen T., and Kronberg L. Occurrence of acidic pharmaceuticals in raw and treated sewages and in receiving waters. Water Res. 39 11 (2005) 2219-2228
14. Lishman L., Smyth S.A., Sarafin K., Kleywegt S., Toito J., Peart T., Lee B., Servos M., Beland M., and Seto P. Occurrence and reductions of pharmaceuticals and personal care products and estrogens by municipal wastewater treatment plants in Ontario, Canada. Sci. Total Environ. 367 1-2 (2006) 544-558
15. Loraine G.A., and Pettigrove M.E. Seasonal variations in concentrations of pharmaceuticals and personal care products in drinking water and reclaimed wastewater in Southern California. Environ. Sci. Technol. 40 3 (2006) 687-695
16. Mazzoni C., and Bandini S. On nanofiltration Desal-5 DK performances with calcium chloride-water solutions. Sep. Purif. Technol. 52 2 (2006) 232-240
17. Nghiem L.D., Schäfer A.I., and Elimelech M. Pharmaceutical retention mechanisms by nanofiltration membranes. Environ. Sci. Technol. 39 19 (2005) 7698-7705
18. Nghiem L.D., Schäfer A.I., and Elimelech M. Role of electrostatic interactions in the retention of pharmaceutically active contaminants by a loose nanofiltration membrane. J. Membr. Sci. 286 1-2 (2006) 52-59
19. Nghiem L.D., and Hawkes S. Effects of membrane fouling on the nanofiltration of pharmaceutically active compounds (PhACs): mechanisms and role of membrane pore size. Sep. Purif. Technol. 57 1 (2007) 176-184
20. Steger-Hartmann T., Kümmerer K., and Hartmann A. Biological degradation of cyclophosphamide and its occurrence in sewage water. Ecotoxicol. Environ. Saf. 36 2 (1997) 174-179
21. Ternes T.A., Meisenheimer M., McDowell D., Sacher F., Brauch H.J., Haist-Gulde B., Wilme G.U., and Zulei-Seibert N. Removal of pharmaceuticals during drinking water treatment. Environ. Sci. Technol. 36 17 (2002) 3855-3863
22. d) for pharmaceuticals and musk fragrances in sewage sludge. Water Res. 38 19 (2004) 4075-4084
23. Van der Bruggen B., Schaep J., and Wilms D. Nanofiltration as a treatment method for the removal of pesticides from ground waters. Desalination 117 1 (1998) 139-147
24. Van der Bruggen B., and Vandecasteele C. Removal of pollutant from surface water and ground water by nanofiltration: overview of possible applications in the drinking water industry. Environ. Pollut. 122 3 (2003) 435-445
25. Verliefde A.R.D., Heijman S.G.J., Cornelissen E.R., Amy G., Van der Bruggen B., and Van Dijk J.C. Influence of electrostatic interactions on the rejection with NF and assessment of the removal efficiency during NF/GAC treatment of pharmaceutically active compounds in surface water. Water Res. 41 15 (2007) 3227-3240
26. Vieno N., Tuhkanen T., and Kronberg L. Elimination of pharmaceuticals in sewage treatment plants in Finland. Water Res. 41 5 (2007) 1001-1012
27. Yoon Y., Westerhoff P., Snyder S.A., and Wert E.C. Nanofiltration and ultrafiltration of endocrine disrupting compounds, pharmaceuticals and personal care products. J. Membr. Sci. 270 1 (2006) 88-100
28. Zuccato E., Calamari D., Natangelo M., and Fanelli R. Presence of therapeutic drugs in the environment. The Lancet 355 9217 (2000) 1789-1790